Published in Proc Natl Acad Sci U S A on February 19, 2004
Targeted polypharmacology: discovery of dual inhibitors of tyrosine and phosphoinositide kinases. Nat Chem Biol (2008) 3.84
Targeting the PI3K/Akt/mTOR pathway: effective combinations and clinical considerations. Drug Resist Updat (2007) 3.78
Effective and selective targeting of leukemia cells using a TORC1/2 kinase inhibitor. Nat Med (2010) 3.26
Nilotinib and MEK inhibitors induce synthetic lethality through paradoxical activation of RAF in drug-resistant chronic myeloid leukemia. Cancer Cell (2011) 2.57
Pim and Akt oncogenes are independent regulators of hematopoietic cell growth and survival. Blood (2005) 2.09
Mammalian target of rapamycin controls dendritic cell development downstream of Flt3 ligand signaling. Immunity (2010) 2.05
Role of mTOR in anticancer drug resistance: perspectives for improved drug treatment. Drug Resist Updat (2008) 1.90
Critical roles for mTORC2- and rapamycin-insensitive mTORC1-complexes in growth and survival of BCR-ABL-expressing leukemic cells. Proc Natl Acad Sci U S A (2010) 1.75
mTOR signaling: implications for cancer and anticancer therapy. Br J Cancer (2006) 1.72
BCR-ABL suppresses autophagy through ATF5-mediated regulation of mTOR transcription. Blood (2011) 1.61
Therapeutic options for chronic myeloid leukemia: focus on imatinib (Glivec, Gleevectrade mark). Ther Clin Risk Manag (2008) 1.59
Ablation of PI3K blocks BCR-ABL leukemogenesis in mice, and a dual PI3K/mTOR inhibitor prevents expansion of human BCR-ABL+ leukemia cells. J Clin Invest (2008) 1.56
FLT3 inhibition and mechanisms of drug resistance in mutant FLT3-positive AML. Drug Resist Updat (2009) 1.47
Developmental stage-specific interplay of GATA1 and IGF signaling in fetal megakaryopoiesis and leukemogenesis. Genes Dev (2010) 1.42
Oncogenic Kit signaling and therapeutic intervention in a mouse model of gastrointestinal stromal tumor. Proc Natl Acad Sci U S A (2006) 1.42
Mammalian target of rapamycin inhibitors and their potential role in therapy in leukaemia and other haematological malignancies. Br J Haematol (2009) 1.25
Targeting the PI3K/AKT/mTOR signaling axis in children with hematologic malignancies. Paediatr Drugs (2012) 1.22
Suppression of programmed cell death 4 (PDCD4) protein expression by BCR-ABL-regulated engagement of the mTOR/p70 S6 kinase pathway. J Biol Chem (2008) 1.21
RAD001 (everolimus) inhibits tumour growth in xenograft models of human hepatocellular carcinoma. J Cell Mol Med (2008) 1.19
A common phosphotyrosine signature for the Bcr-Abl kinase. Blood (2006) 1.16
FoxO tumor suppressors and BCR-ABL-induced leukemia: a matter of evasion of apoptosis. Biochim Biophys Acta (2007) 1.13
Synergistic growth inhibition by Iressa and Rapamycin is modulated by VHL mutations in renal cell carcinoma. Br J Cancer (2005) 1.12
Potentiation of antileukemic therapies by the dual PI3K/PDK-1 inhibitor, BAG956: effects on BCR-ABL- and mutant FLT3-expressing cells. Blood (2008) 1.09
A novel mechanism for Bcr-Abl action: Bcr-Abl-mediated induction of the eIF4F translation initiation complex and mRNA translation. Oncogene (2006) 1.08
Mechanisms of resistance to FLT3 inhibitors. Drug Resist Updat (2009) 1.05
Differential regulation of the p70 S6 kinase pathway by interferon alpha (IFNalpha) and imatinib mesylate (STI571) in chronic myelogenous leukemia cells. Blood (2005) 1.03
AMPK in BCR-ABL expressing leukemias. Regulatory effects and therapeutic implications. Oncotarget (2011) 1.02
AKT kinase pathway: a leading target in cancer research. ScientificWorldJournal (2013) 1.01
mTOR signaling is activated by FLT3 kinase and promotes survival of FLT3-mutated acute myeloid leukemia cells. Mol Cancer (2010) 1.00
Inhibition of SAPK2/p38 enhances sensitivity to mTORC1 inhibition by blocking IRES-mediated translation initiation in glioblastoma. Mol Cancer Ther (2011) 0.99
Genetic reduction of class IA PI-3 kinase activity alters fetal hematopoiesis and competitive repopulating ability of hematopoietic stem cells in vivo. Blood (2005) 0.98
Antileukemic effects of AMPK activators on BCR-ABL-expressing cells. Blood (2011) 0.96
Present and Future of EGFR Inhibitors for Head and Neck Squamous Cell Cancer. J Oncol (2012) 0.95
Alternative approaches to eradicating the malignant clone in chronic myeloid leukemia: tyrosine-kinase inhibitor combinations and beyond. Hematology Am Soc Hematol Educ Program (2013) 0.91
The evolving landscape in the therapy of acute myeloid leukemia. Protein Cell (2013) 0.90
GILZ inhibits the mTORC2/AKT pathway in BCR-ABL(+) cells. Oncogene (2011) 0.89
Effective targeting of STAT5-mediated survival in myeloproliferative neoplasms using ABT-737 combined with rapamycin. Leukemia (2010) 0.88
Combining the FLT3 inhibitor PKC412 and the triterpenoid CDDO-Me synergistically induces apoptosis in acute myeloid leukemia with the internal tandem duplication mutation. Mol Cancer Res (2010) 0.87
Suppression of interferon (IFN)-inducible genes and IFN-mediated functional responses in BCR-ABL-expressing cells. J Biol Chem (2008) 0.87
Proangiogenic stimulation of bone marrow endothelium engages mTOR and is inhibited by simultaneous blockade of mTOR and NF-kappaB. Blood (2005) 0.86
PI3K/mTOR pathway inhibitors sensitize chronic myeloid leukemia stem cells to nilotinib and restore the response of progenitors to nilotinib in the presence of stem cell factor. Cell Death Dis (2013) 0.86
Signal transduction in the chronic leukemias: implications for targeted therapies. Curr Hematol Malig Rep (2013) 0.84
S6K1 determines the metabolic requirements for BCR-ABL survival. Oncogene (2012) 0.83
Emerging FMS-like tyrosine kinase 3 inhibitors for the treatment of acute myelogenous leukemia. Expert Opin Emerg Drugs (2011) 0.79
AKT1 induces caspase-mediated cleavage of the CDK inhibitor p27Kip1 during cell cycle progression in leukemia cells transformed by FLT3-ITD. Leuk Res (2011) 0.77
Synergistic roles of p53 and HIF1α in human renal cell carcinoma-cell apoptosis responding to the inhibition of mTOR and MDM2 signaling pathways. Drug Des Devel Ther (2016) 0.76
Isobologram analysis of triple therapies. Radiat Oncol (2006) 0.76
Regulatory effects of sestrin 3 (SESN3) in BCR-ABL expressing cells. PLoS One (2013) 0.76
Grb10 is involved in BCR-ABL-positive leukemia in mice. Leukemia (2014) 0.76
The exploration of network motifs as potential drug targets from post-translational regulatory networks. Sci Rep (2016) 0.75
The additive damage model: a mathematical model for cellular responses to drug combinations. J Theor Biol (2014) 0.75
Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med (2002) 24.88
Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med (2003) 17.23
Human chronic myelogenous leukemia cell-line with positive Philadelphia chromosome. Blood (1975) 15.95
Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell (2002) 13.03
Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med (2001) 11.88
Identification of the tuberous sclerosis complex-2 tumor suppressor gene product tuberin as a target of the phosphoinositide 3-kinase/akt pathway. Mol Cell (2002) 11.65
Two TOR complexes, only one of which is rapamycin sensitive, have distinct roles in cell growth control. Mol Cell (2002) 11.59
Raptor, a binding partner of target of rapamycin (TOR), mediates TOR action. Cell (2002) 11.50
A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med (2003) 11.17
Regulation of translation initiation by FRAP/mTOR. Genes Dev (2001) 9.40
Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med (2002) 8.86
Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med (2001) 7.88
Mechanisms of autoinhibition and STI-571/imatinib resistance revealed by mutagenesis of BCR-ABL. Cell (2003) 5.71
SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo. Blood (2003) 5.07
Tuberous sclerosis complex-1 and -2 gene products function together to inhibit mammalian target of rapamycin (mTOR)-mediated downstream signaling. Proc Natl Acad Sci U S A (2002) 4.93
Fusion of PDGF receptor beta to a novel ets-like gene, tel, in chronic myelomonocytic leukemia with t(5;12) chromosomal translocation. Cell (1994) 4.64
A direct linkage between the phosphoinositide 3-kinase-AKT signaling pathway and the mammalian target of rapamycin in mitogen-stimulated and transformed cells. Cancer Res (2000) 4.62
Protein phosphatase 2A interacts with the 70-kDa S6 kinase and is activated by inhibition of FKBP12-rapamycinassociated protein. Proc Natl Acad Sci U S A (1999) 3.49
The rapamycin-sensitive signal transduction pathway as a target for cancer therapy. Oncogene (2000) 3.40
Transformation of hematopoietic cells by BCR/ABL requires activation of a PI-3k/Akt-dependent pathway. EMBO J (1997) 3.34
Will mTOR inhibitors make it as cancer drugs? Cancer Cell (2003) 3.15
Inhibition of mutant FLT3 receptors in leukemia cells by the small molecule tyrosine kinase inhibitor PKC412. Cancer Cell (2002) 3.09
Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta. N Engl J Med (2002) 3.08
Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia. J Clin Invest (2000) 2.90
A FLT3-targeted tyrosine kinase inhibitor is cytotoxic to leukemia cells in vitro and in vivo. Blood (2002) 2.76
Critical role for Gab2 in transformation by BCR/ABL. Cancer Cell (2002) 2.42
CT53518, a novel selective FLT3 antagonist for the treatment of acute myelogenous leukemia (AML). Cancer Cell (2002) 1.91
Overcoming STI571 resistance with the farnesyl transferase inhibitor SCH66336. Blood (2002) 1.72
Phosphatidylinositol-3 kinase activity is regulated by BCR/ABL and is required for the growth of Philadelphia chromosome-positive cells. Blood (1995) 1.69
The rapamycin-binding domain governs substrate selectivity by the mammalian target of rapamycin. Mol Cell Biol (2002) 1.68
New role for Shc in activation of the phosphatidylinositol 3-kinase/Akt pathway. Mol Cell Biol (2000) 1.68
Bcr-Abl kinase modulates the translation regulators ribosomal protein S6 and 4E-BP1 in chronic myelogenous leukemia cells via the mammalian target of rapamycin. Cancer Res (2003) 1.64
Development of anticancer drugs targeting the MAP kinase pathway. Oncogene (2000) 1.63
Initiation of deregulated growth of multipotent progenitor cells by bcr-abl in vitro. Science (1992) 1.62
Hematologic malignancies. Curr Opin Hematol (2001) 1.52
Role of FLT3 in leukemia. Curr Opin Hematol (2002) 1.52
Crkl is the major tyrosine-phosphorylated protein in neutrophils from patients with chronic myelogenous leukemia. J Biol Chem (1994) 1.43
Establishment of a murine model for therapy-treated chronic myelogenous leukemia using the tyrosine kinase inhibitor STI571. Blood (2001) 1.41
Clinical pharmacokinetics and therapeutic drug monitoring of sirolimus. Clin Ther (2000) 1.36
Inhibition of the Bcr-Abl tyrosine kinase as a therapeutic strategy for CML. Oncogene (2002) 1.24
Studying the pathogenesis of BCR-ABL+ leukemia in mice. Oncogene (2002) 1.22
Identification of CRKL as the constitutively phosphorylated 39-kD tyrosine phosphoprotein in chronic myelogenous leukemia cells. Blood (1994) 1.20
Efficacy of STI571, an abl tyrosine kinase inhibitor, in conjunction with other antileukemic agents against bcr-abl-positive cells. Blood (2000) 1.20
The Bcr-Abl tyrosine kinase activates mitogenic signaling pathways and stimulates G1-to-S phase transition in hematopoietic cells. Oncogene (1997) 1.17
Synergistic activity of the new ABL-specific tyrosine kinase inhibitor STI571 and chemotherapeutic drugs on BCR-ABL-positive chronic myelogenous leukemia cells. Leukemia (2001) 1.04
Biology of BCR-ABL. Blood Rev (1999) 0.89
Effects of combinations of therapeutic agents on the proliferation of progenitor cells in chronic myeloid leukaemia. Br J Haematol (2002) 0.84
Co-treatment with As2O3 enhances selective cytotoxic effects of STI-571 against Brc-Abl-positive acute leukemia cells. Leukemia (2001) 0.83
Quantitative monitoring of BCR/ABL transcript during STI-571 therapy. Leuk Lymphoma (2002) 0.78
Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell (2007) 17.98
Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell (2005) 17.41
FoxOs are critical mediators of hematopoietic stem cell resistance to physiologic oxidative stress. Cell (2007) 12.33
Transformation from committed progenitor to leukaemia stem cell initiated by MLL-AF9. Nature (2006) 11.90
Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. Nature (2009) 11.46
A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med (2003) 11.17
Molecular profiling of diffuse large B-cell lymphoma identifies robust subtypes including one characterized by host inflammatory response. Blood (2004) 11.07
SF3B1 and other novel cancer genes in chronic lymphocytic leukemia. N Engl J Med (2011) 11.07
Clinical effect of point mutations in myelodysplastic syndromes. N Engl J Med (2011) 9.90
Evolution and impact of subclonal mutations in chronic lymphocytic leukemia. Cell (2013) 9.24
FoxOs are lineage-restricted redundant tumor suppressors and regulate endothelial cell homeostasis. Cell (2007) 8.94
Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med (2006) 8.26
JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. N Engl J Med (2007) 8.18
Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell (2005) 7.99
MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS Med (2006) 7.95
Activating mutations in ALK provide a therapeutic target in neuroblastoma. Nature (2008) 6.80
NOTCH1 directly regulates c-MYC and activates a feed-forward-loop transcriptional network promoting leukemic cell growth. Proc Natl Acad Sci U S A (2006) 6.80
Gene expression signatures define novel oncogenic pathways in T cell acute lymphoblastic leukemia. Cancer Cell (2002) 6.64
Synthetic lethal interaction between oncogenic KRAS dependency and STK33 suppression in human cancer cells. Cell (2009) 6.55
The roles of FLT3 in hematopoiesis and leukemia. Blood (2002) 6.14
Age-related clonal hematopoiesis associated with adverse outcomes. N Engl J Med (2014) 6.12
Community-based therapy for multidrug-resistant tuberculosis in Lima, Peru. N Engl J Med (2003) 6.07
MOZ-TIF2, but not BCR-ABL, confers properties of leukemic stem cells to committed murine hematopoietic progenitors. Cancer Cell (2004) 5.98
MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients. Blood (2006) 5.95
Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies. Blood (2009) 5.72
Tyrosine phosphorylation inhibits PKM2 to promote the Warburg effect and tumor growth. Sci Signal (2009) 5.57
STAT3 signalling is required for leptin regulation of energy balance but not reproduction. Nature (2003) 5.27
Drug development and clinical trials--the path to an approved cancer drug. Nat Rev Clin Oncol (2012) 4.98
Direct inhibition of the NOTCH transcription factor complex. Nature (2009) 4.82
Highly sensitive method for genomewide detection of allelic composition in nonpaired, primary tumor specimens by use of affymetrix single-nucleotide-polymorphism genotyping microarrays. Am J Hum Genet (2007) 4.52
Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients. Proc Natl Acad Sci U S A (2008) 4.43
Growth suppression of pre-T acute lymphoblastic leukemia cells by inhibition of notch signaling. Mol Cell Biol (2003) 4.43
tp53 mutant zebrafish develop malignant peripheral nerve sheath tumors. Proc Natl Acad Sci U S A (2005) 4.15
Mathematical models of protein kinase signal transduction. Mol Cell (2002) 4.08
Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: an intergroup trial (E1193). J Clin Oncol (2003) 4.07
Safety and efficacy of TG101348, a selective JAK2 inhibitor, in myelofibrosis. J Clin Oncol (2011) 4.06
Tumor cell-specific bioluminescence platform to identify stroma-induced changes to anticancer drug activity. Nat Med (2010) 4.00
Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders. Nat Rev Cancer (2007) 3.89
Expression of Jak2V617F causes a polycythemia vera-like disease with associated myelofibrosis in a murine bone marrow transplant model. Blood (2006) 3.88
Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412. Blood (2004) 3.84
Germline gain-of-function mutations in SOS1 cause Noonan syndrome. Nat Genet (2006) 3.81
Genome-wide translocation sequencing reveals mechanisms of chromosome breaks and rearrangements in B cells. Cell (2011) 3.81
The retinoblastoma binding protein RBP2 is an H3K4 demethylase. Cell (2007) 3.79
Inhibition of FLT3 in MLL. Validation of a therapeutic target identified by gene expression based classification. Cancer Cell (2003) 3.75
Drug therapy for acute myeloid leukemia. Blood (2005) 3.74
Neuronal PTP1B regulates body weight, adiposity and leptin action. Nat Med (2006) 3.66
PTP1B regulates leptin signal transduction in vivo. Dev Cell (2002) 3.61
Mouse model of Noonan syndrome reveals cell type- and gene dosage-dependent effects of Ptpn11 mutation. Nat Med (2004) 3.55
PDGFRs are critical for PI3K/Akt activation and negatively regulated by mTOR. J Clin Invest (2007) 3.54
Conditional expression of oncogenic K-ras from its endogenous promoter induces a myeloproliferative disease. J Clin Invest (2004) 3.47
The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both "atypical" myeloproliferative disorders and myelodysplastic syndromes. Blood (2005) 3.47
Physiological Jak2V617F expression causes a lethal myeloproliferative neoplasm with differential effects on hematopoietic stem and progenitor cells. Cancer Cell (2010) 3.46
Integrative genomic and proteomic analyses identify targets for Lkb1-deficient metastatic lung tumors. Cancer Cell (2010) 3.40
c-MET mutational analysis in small cell lung cancer: novel juxtamembrane domain mutations regulating cytoskeletal functions. Cancer Res (2003) 3.39
Myeloproliferative disorders. Blood (2008) 3.37
Second generation inhibitors of BCR-ABL for the treatment of imatinib-resistant chronic myeloid leukaemia. Nat Rev Cancer (2007) 3.36
Familial cancer associated with a polymorphism in ARLTS1. N Engl J Med (2005) 3.35
Loss of Runx1 perturbs adult hematopoiesis and is associated with a myeloproliferative phenotype. Blood (2005) 3.32
Genetics of myeloid leukemias. Annu Rev Genomics Hum Genet (2002) 3.31
High-throughput sequence analysis of the tyrosine kinome in acute myeloid leukemia. Blood (2008) 3.30
Identification of driver and passenger mutations of FLT3 by high-throughput DNA sequence analysis and functional assessment of candidate alleles. Cancer Cell (2007) 3.23
Activating mutations of the noonan syndrome-associated SHP2/PTPN11 gene in human solid tumors and adult acute myelogenous leukemia. Cancer Res (2004) 3.20
PML/RARalpha and FLT3-ITD induce an APL-like disease in a mouse model. Proc Natl Acad Sci U S A (2002) 3.19
Core-binding factors in haematopoiesis and leukaemia. Nat Rev Cancer (2002) 3.18
Imaging sites of receptor dephosphorylation by PTP1B on the surface of the endoplasmic reticulum. Science (2002) 3.12
A germline JAK2 SNP is associated with predisposition to the development of JAK2(V617F)-positive myeloproliferative neoplasms. Nat Genet (2009) 3.10
Inhibition of mutant FLT3 receptors in leukemia cells by the small molecule tyrosine kinase inhibitor PKC412. Cancer Cell (2002) 3.09
High frequency of PTEN, PI3K, and AKT abnormalities in T-cell acute lymphoblastic leukemia. Blood (2009) 3.02
Leukaemia stem cells and the evolution of cancer-stem-cell research. Nat Rev Cancer (2005) 3.01
Genetics of myeloid malignancies: pathogenetic and clinical implications. J Clin Oncol (2005) 2.94
Expression of a homodimeric type I cytokine receptor is required for JAK2V617F-mediated transformation. Proc Natl Acad Sci U S A (2005) 2.94
Validation of a prognostic model and the impact of mutations in patients with lower-risk myelodysplastic syndromes. J Clin Oncol (2012) 2.92
The leukemic stem cell niche: current concepts and therapeutic opportunities. Blood (2009) 2.85
Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine model. Cancer Res (2002) 2.83
Shp2 regulates SRC family kinase activity and Ras/Erk activation by controlling Csk recruitment. Mol Cell (2004) 2.82
Efficacy of TG101348, a selective JAK2 inhibitor, in treatment of a murine model of JAK2V617F-induced polycythemia vera. Cancer Cell (2008) 2.80
AKT/FOXO signaling enforces reversible differentiation blockade in myeloid leukemias. Cell (2011) 2.77
The tyrosine phosphatase Shp2 (PTPN11) in cancer. Cancer Metastasis Rev (2008) 2.74
PKC412 overcomes resistance to imatinib in a murine model of FIP1L1-PDGFRα-induced myeloproliferative disease. Cancer Cell (2003) 2.70